Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial

被引：0

作者：

Verma, S. ^{[1
]}

Leiter, L. A. ^{[2
]}

Mazer, C. D. ^{[2
]}

Bain, S. C. ^{[3
]}

Buse, J. ^{[4
]}

Marso, S. ^{[5
]}

Nauck, M. ^{[6
]}

Zinman, B. ^{[2
]}

Bosch-Traberg, H. ^{[7
]}

Frimer-Larsen, H. ^{[7
]}

Michelsen, M. M. ^{[7
]}

Bhatt, D. L. ^{[8
]}

机构：

[1] St Michaels Hosp, Cardiac Surg, Toronto, ON, Canada

[2] Univ Toronto, Toronto, ON, Canada

[3] Swansea Univ, Swansea, W Glam, Wales

[4] Univ North Carolina Hosp, Chapel Hill, NC USA

[5] HCA Midwest Hlth Heart & Vasc Inst, Kansas City, MO USA

[6] RUB, Bochum, Germany

[7] Novo Nordisk AS, Soborg, Denmark

[8] Harvard Med Sch, Boston, MA 02115 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P2858

引用

页码：598 / 598

页数：1